Loading
Latest filing published 17 Apr 2018 for Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.), €223.
No signal scores available.
This profile gathers the share dealings of Patrick Charles Frankham in Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.). Over a trading history stretching from 24 July 2014 to 10 April 2018, the count stands at 3 filings.
Every open-market trade on record is a purchase: 1 purchase worth €223, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2018, the count stands at 1 purchase and no sales.
On 17 April 2018 came the latest disclosure, an open-market purchase for €223 in Pivot Pharmaceuticals Inc. (formerly Neurokine Pharmaceuticals Inc.). Every figure here comes from the filings published by SEDI and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations